Trimodal therapy (TMT) is a treatment option for some patients with muscle-invasive bladder cancer. This approach combines aggressive transurethral resection, radiation therapy, and radio-sensitizing chemotherapy as an alternative to radical cystectomy with urinary diversion. In the absence of head-to-head level 1 evidence, there is now a growing body of retrospective data suggesting worse survival rates with this technique.1,2 Now added to this are data suggesting higher costs as well.3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Cole AP, Trinh Q. Trimodal Therapy for Bladder Cancer: You Get What You Don’t Pay For. JAMA Surg. Published online August 01, 2019154(8):e191637. doi:10.1001/jamasurg.2019.1637
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: